No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro

被引:43
作者
Peterson, Dylan W. [1 ]
Ando, D. Michael [1 ]
Taketa, Daryl A. [1 ]
Zhou, Hongjun [2 ]
Dahlquist, Fredrick W. [2 ]
Lew, John [1 ]
机构
[1] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA
[2] Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; neurotoxicity; NMR; protein kinase; proteolysis; CYCLIN-DEPENDENT KINASE-5; DIRECTED PROTEIN-KINASE; ACTIVATOR P35; SUBSTRATE-SPECIFICITY; MOUSE MODEL; P25; ALZHEIMERS; DISEASE; SITES; NEUROFILAMENT;
D O I
10.1073/pnas.0912718107
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CDK5/p35 is a cyclin-dependent kinase essential for normal neuron function. Proteolysis of the p35 subunit in vivo results in CDK5/p25 that causes neurotoxicity associated with a number of neurodegenerative diseases. Whereas the mechanism by which conversion of p35 to p25 leads to toxicity is unknown, there is common belief that CDK5/p25 is catalytically hyperactive compared to CDK5/p35. Here, we have compared the steady-state kinetic parameters of CDK5/p35 and CDK5/p25 towards both histone H1, the best known substrate for both enzymes, and the microtubule-associated protein, tau, a physiological substrate whose in vivo phosphorylation is relevant to Alzheimer's disease. We show that the kinetics of both enzymes are the same towards either substrate in vitro. Furthermore, both enzymes display virtually identical kinetics towards individual phosphorylation sites in tau monitored by NMR. We conclude that conversion of p35 to p25 does not alter the catalytic efficiency of the CDK5 catalytic subunit by using histone H1 or tau as substrates, and that neurotoxicity associated with CDK5/p25 is unlikely attributable to CDK5 hyperactivation, as measured in vitro.
引用
收藏
页码:2884 / 2889
页数:6
相关论文
共 50 条
  • [21] p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity
    Zhang, Lingyan
    Liu, Wen
    Szumlinski, Karen K.
    Lew, John
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (49) : 20041 - 20046
  • [22] Cdk5 Inhibitory Peptide (CIP) Inhibits Cdk5/p25 Activity Induced by High Glucose in Pancreatic Beta Cells and Recovers Insulin Secretion from p25 Damage
    Zheng, Ya-Li
    Li, Congyu
    Hu, Ya-Fang
    Cao, Li
    Wang, Hui
    Li, Bo
    Lu, Xiao-Hua
    Bao, Li
    Luo, Hong-Yan
    Shukla, Varsha
    Amin, Niranjana D.
    Pant, Harish C.
    PLOS ONE, 2013, 8 (09):
  • [23] Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia
    Seo, Jinsoo
    Kritskiy, Oleg
    Watson, L. Ashley
    Barker, Scarlett J.
    Dey, Dilip
    Raja, Waseem K.
    Lin, Yuan-Ta
    Ko, Tak
    Cho, Sukhee
    Penney, Jay
    Silva, M. Catarina
    Sheridan, Steven D.
    Lucente, Diane
    Gusella, James F.
    Dickerson, Bradford C.
    Haggarty, Stephen J.
    Tsai, Li-Huei
    JOURNAL OF NEUROSCIENCE, 2017, 37 (41) : 9917 - 9924
  • [24] CDK5 activator protein p25 preferentially binds and activates GSK3β
    Chow, Hei-Man
    Guo, Dong
    Zhou, Jie-Chao
    Zhang, Guan-Yun
    Li, Hui-Fang
    Herrup, Karl
    Zhang, Jie
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (45) : E4887 - E4895
  • [25] Addressing the complex etiology of Alzheimer's disease: the role of p25/Cdk5
    Mungenast, Alison E.
    Tsai, Li-Huei
    FUTURE NEUROLOGY, 2011, 6 (04) : 481 - 496
  • [26] Tau Phosphorylation by cdk5 and Fyn in Response to Amyloid Peptide Aβ25-35: Involvement of Lipid Rafts
    Hernandez, Paula
    Lee, Gloria
    Sjoberg, Marcela
    Maccioni, Ricardo B.
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (01) : 149 - 156
  • [27] Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation
    Sun, Li-Hua
    Ban, Tao
    Liu, Cheng-Di
    Chen, Qing-Xin
    Wang, Xu
    Yan, Mei-Ling
    Hu, Xue-Ling
    Su, Xiao-Lin
    Bao, Ya-Nan
    Sun, Lin-Lin
    Zhao, Lin-Jing
    Pei, Shuang-Chao
    Jiang, Xue-Mei
    Zong, De-Kang
    Ai, Jing
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 (06) : 1139 - 1151
  • [28] The Cdk5/p35 Kinases Modulate Leptin-Induced STAT3 Signaling
    He, Yi
    Kastin, Abba J.
    Hsuchou, Hung
    Pan, Weihong
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2009, 39 (1-2) : 49 - 58
  • [29] Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora
    Shrestha, Sabina
    Natarajan, Sathishkumar
    Park, Ji-Hae
    Lee, Dae-Young
    Cho, Jin-Gyeong
    Kim, Geum-Soog
    Jeon, Yong-Jin
    Yeon, Seung-Woo
    Yang, Deok-Chun
    Baek, Nam-In
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (18) : 5150 - 5154
  • [30] Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders
    Zeb, Amir
    Son, Minky
    Yoon, Sanghwa
    Kim, Ju Hyun
    Park, Seok Ju
    Lee, Keun Woo
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2019, 17 : 579 - 590